Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to “Sell” at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities research analysts also recently issued reports on CMPX. Citigroup assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating on the stock. JMP Securities set a $10.00 target price on Compass Therapeutics in a research note on Wednesday, December 3rd. Lifesci Capital started coverage on Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target on the stock. William Blair initiated coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating for the company. Finally, D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Trading Down 1.7%

Shares of Compass Therapeutics stock opened at $5.70 on Friday. The stock has a market capitalization of $1.01 billion, a P/E ratio of -12.67 and a beta of 1.45. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $6.25. The business’s fifty day moving average price is $5.19 and its 200 day moving average price is $4.02.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. As a group, sell-side analysts predict that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CMPX. Russell Investments Group Ltd. increased its holdings in shares of Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning bought a new position in Compass Therapeutics during the second quarter worth $30,000. Strs Ohio acquired a new position in Compass Therapeutics in the first quarter worth $34,000. Apollon Wealth Management LLC bought a new stake in Compass Therapeutics during the third quarter valued at $35,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics during the third quarter valued at $37,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.